NCT03099499 2024-12-24
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Fox Chase Cancer Center
Phase 2 Terminated
Clinical Trials
3 trialsNCT03485729 2024-12-24
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
Jazz Pharmaceuticals
Phase 2 Terminated
NCT03394027 2022-08-23
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed